Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis

Tools
- Tools
+ Tools

Kihm, L. P., Muller-Krebs, S., Klein, Julia, Ehrlich, G., Mertes, L., Gross, Marie-Luise, Antonysunil, Adaikalakoteswari, Thornalley, Paul J., Hammes, H.-P., Nawroth, P. P., Zeier, M. and Schwenger, Vedat (2011) Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. Journal of the American Society of Nephrology, Vol.22 (No.5). pp. 914-926. doi:10.1681/ASN.2010070750

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1681/ASN.2010070750

Request Changes to record.

Abstract

Residual renal function and the integrity of the peritoneal membrane contribute to morbidity and mortality among patients treated with peritoneal dialysis. Glucose and its degradation products likely contribute to the deterioration of the remnant kidney and damage to the peritoneum. Benfotiamine decreases glucose-induced tissue damage, suggesting the potential for benefit in peritoneal dialysis. Here, in a model of peritoneal dialysis in uremic rats, treatment with benfotiamine decreased peritoneal fibrosis, markers of inflammation, and neovascularization, resulting in improved characteristics of peritoneal transport. Furthermore, rats treated with benfotiamine exhibited lower expression of advanced glycation endproducts and their receptor in the peritoneum and the kidney, reduced glomerular and tubulointerstitial damage, and less albuminuria. Increased activity of transketolase in tissue and blood contributed to the protective effects of benfotiamine. In primary human peritoneal mesothelial cells, the addition of benfotiamine led to enhanced transketolase activity and decreased expression of advanced glycation endproducts and their receptor. Taken together, these data suggest that benfotiamine protects the peritoneal membrane and remnant kidney in a rat model of peritoneal dialysis and uremia.

Item Type: Journal Article
Subjects: R Medicine > RB Pathology
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine
Library of Congress Subject Headings (LCSH): Peritoneal dialysis, Vascular endothelium, Oxidative stress, Hyperglycemia, Vitamin B1
Journal or Publication Title: Journal of the American Society of Nephrology
Publisher: American Society of Nephrology
ISSN: 1046-6673
Official Date: May 2011
Dates:
DateEvent
May 2011Published
Volume: Vol.22
Number: No.5
Page Range: pp. 914-926
DOI: 10.1681/ASN.2010070750
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Gambro (Firm), Worwag Pharma

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us